1 Result: Pulmonx
Pulmonx Beats Estimates; Strategic Move Boosts TransCode Therapeutics
October 30th, 2023
Pulmonx Corporation (Nasdaq: LUNG) reported a narrower loss than expected in the third quarter of 2023, posting a loss of $(0.39) per share, surpassing the consensus estimate loss of $(0.43) per share. The company's quarterly sales stood at $17.67 mi. Read more
Load More Content
Want To Find Some News?
Recent Post
-
September 18th, 2025
Crown Equity Holdings, Inc. Announces Letter of Intent with Stewart Holdings LLP
September 16th, 2025September 15th, 2025Crown Equity Holdings, Inc. Announces Letter of Intent with BioHarvest Naturals Corp.
September 15th, 2025Earnings Watch: FedEx, Darden Restaurants, and FactSet Gear Up
September 14th, 2025
Member Login